International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1305-1313 , April 2010

Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082

  • Lawrence B. Marks, M.D.

      Affiliations

    • Radiation Oncology, University of North Carolina, Chapel Hill, NC
    • Department of Radiation Oncology, Duke University, Durham, NC
    • Corresponding Author InformationReprint requests to: Lawrence B. Marks, M.D., Department of Radiation Oncology, University of North Carolina School of Medicine, CB #7512, Chapel Hill, NC 27599-7512. Tel: (919) 966-0400; Fax: (919) 966-7681
    • ,
  • Constance Cirrincione, M.S.

      Affiliations

    • Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC
    • ,
  • Thomas J. Fitzgerald, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Massachusetts, Worcester, MA
    • Quality Assurance Review Center, Providence, RI
    • ,
  • Frances Laurie

      Affiliations

    • Quality Assurance Review Center, Providence, RI
    • ,
  • Arvin S. Glicksman, M.D.

      Affiliations

    • Quality Assurance Review Center, Providence, RI
    • Rhode Island Cancer Council, Pawtucket, RI
    • ,
  • James Vredenburgh, M.D.

      Affiliations

    • Department of Medical Oncology, Duke University, Durham, NC
    • ,
  • Leonard R. Prosnitz, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University, Durham, NC
    • ,
  • Elizabeth J. Shpall, M.D.

      Affiliations

    • Adult Bone Marrow Transplant Program, University of Colorado, Denver, CO
    • ,
  • Michael Crump, M.D.

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
    • ,
  • Paul G. Richardson, M.D.

      Affiliations

    • Dana Farber Cancer Institute, Boston, MA
    • ,
  • Michael W. Schuster, M.D.

      Affiliations

    • North Shore–Long Island Jewish Medical Center, Manhasset, NY
    • ,
  • Jinli Ma, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University, Durham, NC
    • Department of Radiation Oncology, Fudan University Cancer Hospital, Shanghai, China
    • ,
  • Bercedis L. Peterson, Ph.D.

      Affiliations

    • Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC
    • ,
  • Larry Norton, M.D.

      Affiliations

    • Department of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Steven Seagren, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California at San Diego, San Diego, CA
    • ,
  • I. Craig Henderson, M.D.

      Affiliations

    • University of California at San Francisco (UCSF) Cancer Center, UCSF, San Francisco, CA
    • ,
  • David D. Hurd, M.D.

      Affiliations

    • Departments of Hematology and Oncology, Wake Forest University, Winston-Salem, NC
    • ,
  • William P. Peters, M.D.

      Affiliations

    • Karmanos Cancer Institute, Wayne State University, Detroit, MI
    • ,
  • Cancer and Leukemia Group B, Southwest Oncology Group, and National Cancer Institute of Canada Clinical Trials Group

Received 21 August 2008 ,Revised 3 March 2009 ,Accepted 4 April 2009.

References 

  1. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. Am J Clin Oncol. 1987;10:387–395
  2. Hellman S, Harris JR. Natural history of breast cancer. In:  Harris JR,  Lippman ME,  Morrow M editor. Diseases of the breast. 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2000;p. 407–424
  3. Hoehne F, Chen S, Mabry H, et al. An update on prognosis in breast cancer patients with extensive axillary disease. Breast J. 2008;14:76–80
  4. Rack B, Janni W, Gerber B, et al. Patients with recurrent breast cancer: Does the primary axillary lymph node status predict more aggressive tumor progression?. Breast Cancer Res Treat. 2003;82:83–92
  5. Montero AJ, Rouzier R, Lluch A, et al. The natural history of breast carcinoma in patients with ≥10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: A multi-institutional retrospective study. Cancer. 2005;104:229–235
  6. Geara FB, Nasr E, Tucker SL, et al. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: Influence of clinical presentation on outcome. Int J Radiat Oncol Biol Phys. 2007;68:364–369
  7. Frei E, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med. 1980;69:585–594
  8. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281–1288
  9. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162–1170
  10. Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol. 1992;10:657–670
  11. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997;15:1858–1869
  12. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132–1143
  13. Peters W, Rosner GL, Vredenburgh JJ, et al. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC (Abstr.). Presented at the 37th Annual Meeting of the America Society of Clinical Oncology, May 12–15, 2001, San Francisco, CA.
  14. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23:2191–2200
  15. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–962
  16. Blomqvist C, Tiusanen K, Elomaa I, et al. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. Br J Cancer. 1992;66:1171–1176
  17. Rutqvist LE, Cedermark B, Glas U, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials. Int J Radiat Oncol Biol Phys. 1989;16:629–639
  18. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–955
  19. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–1648
  20. Martinez A, Ahmann D, O'Fallow J. An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer. Int J Radiat Oncol Biol Phys. 1984;10(Suppl. 2):106
  21. McArdle CS, Crawford D, Dykes EH, et al. Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg. 1986;73:264–266
  22. Moss WT, Brand WN, Battifora H. Radiation oncology. Rationale, technique, results. St. Louis: C.V. Mosby; 1979;
  23. Griem KL, Henderson IC, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol. 1987;5:1546–1555
  24. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–253
  25. Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268–2275
  26. Marks LB, Hebert ME, Bentel G, et al. To treat or not to treat the internal mammary nodes: A possible compromise. Int J Radiat Oncol Biol Phys. 1994;29:903–909
  27. Rodenhuis S, Richel DJ, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352:515–521
  28. Winer EP. Quality-of-life research in patients with breast cancer. Cancer. 1994;74:410–415
  29. Damon LE, Hu WW, Stockerl-Goldstein KE, et al. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California. Biol Blood Marrow Transplant. 2000;6:496–505
  30. de Graaf H, Willemse PH, de Vries EG, et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer. 1994;30A:150–153
  31. Roche H, Viens P, Biron P, et al. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control. 2003;10:42–47
  32. Farquhar C, Basser R, Marjoribanks J, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev. 2003;CD003139
  33. Farquhar C, Basser R, Hetrick S, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev. 2003;CD003142
  34. Effects of radiotherapy and surgery in early breast cancer . An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1995;333:1444–1455
  35. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456–1461
  36. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241
  37. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–575
  38. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  39. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. 2005;23:3686–3696.
  40. Overgaard M, Christensen JJ, Johansen H, et al. Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82). Trial. Int J Radiat Oncol Biol Phys. 1990;19:1121–1124
  41. Nielsen HM, Overgaard J, Grau C, et al. Audit of the radiotherapy in the DBCG 82 b&c trials—A validation study of the 1,538 patients randomised to postmastectomy radiotherapy. Radiother Oncol. 2005;76:285–292
  42. Bentel G, Marks LB, Hardenbergh P, et al. Variability of the location of internal mammary vessels and glandular breast tissue in breast cancer patients undergoing routine CT-based treatment planning. Int J Radiat Oncol Biol Phys. 1999;44:1017–1025
  43. Marks LB, Halperin EC, Prosnitz LR, et al. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys. 1992;23:1021–1026
  44. Moreno M, Azinovic I, Lopez-Picazo JM, et al. Radiation therapy after high-dose chemotherapy with peripheral blood stem cell support for high-risk breast cancer. Am J Clin Oncol. 2002;25:347–353
  45. Buchholz TA, Tucker SL, Moore RA, et al. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiant Oncol Biol Phys. 2000;46:337–343
  46. Moore HC, Mick R, Solin LJ, et al. Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol. 1999;10:929–936
  47. Optenberg SA, Thompson IM, Friedrichs P, et al. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274:1599–1605
  48. Demark-Wahnefried W, Schildkraut JM, Iselin CE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer. 1998;83:320–330
  49. Banerjee M, George J, Yee C, et al. Disentangling the effects of race on breast cancer treatment. Cancer. 2007;110:2169–2177
  50. Shen Y, Dong W, Esteva FJ, et al. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. Breast Cancer Res Treat. 2007;102:347–356
  51. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198–1205
  52. Canto JG, Allison JJ, Kiefe CI, et al. Relation of race and sex to the use of reperfusion therapy in Medicare beneficiaries with acute myocardial infarction. N Engl J Med. 2000;342:1094–1100
  53. Peterson ED, Shaw LK, DeLong ER, et al. Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter?. N Engl J Med. 1997;336:480–486
  54. Bickell NA. Race, ethnicity, and disparities in breast cancer: Victories and challenges. Womens Health Issues. 2002;12:238–251
  55. Hahn KM, Bondy ML, Selvan M, et al. Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am J Epidemiol. 2007;166:1035–1044
  56. Gorey KM, Luginaah IN, Schwartz KL, et al. Increased racial differences on breast cancer care and survival in America: Historical evidence consistent with a health insurance hypothesis, 1975-2001. Breast Cancer Res Treat. 2009;113:595–600
  57. Ayanian JZ, Cleary PD, Weissman JS, et al. The effect of patients' preferences on racial differences in access to renal transplantation. N Engl J Med. 1999;341:1661–1669
  58. Griggs JJ, Culakova E, Sorbero ME, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25:2522–2527

 Supported by National Cancer Institute (NCI) Grants CA31946 (to Cancer and Leukemia Group B [CALBG], Richard L. Schilsky, Chairman), CA33601 (to the CALGB Statistical Center, Stephen George, Director), CA29511 (to the Quality Assurance Review Center), CA47577 (to J.V. and L.R.P.), CA42777 (to E.J.S.), CA77202 (to M.C.), CA32291 (to P.G.R.), CA35279 (to M.W.S.), CA77651 (to L.N.), CA11789 (to S.S.), CA60138 (to I.C.H.), CA03927 (to D.D.H.), and CA14028 (to W.P.P.). This manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NCI.

 Conflict of interest: L.B.M. receives honoraria from Varian Medical Systems, and grants from the National Institutes of Health, the Lance Armstrong Foundation, and the U.S. Department of Defense. P.G.R. receives an honorarium from Millennium Pharmaceuticals.

PII: S0360-3016(09)00575-6

doi: 10.1016/j.ijrobp.2009.04.013

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1305-1313 , April 2010

Article Tools

* Image Usage & Resolution